BioHealth News
CEL-SCI Announces Closing of Public Offering
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the closing of its underwritten…
Read MoreUSM Chancellor Jay Perman: The Reasons for Undergraduate Research
University research has grabbed plenty of headlines over the past few months. Not for the breakthroughs that propel so much of American innovation. Not…
Read MoreSenseonics Raises $77.8M Through Public Offering and Private Placement
GERMANTOWN, Md., May 21, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of…
Read MoreReGelTec Receives CE Mark for HYDRAFIL® System to Treat Chronic Low Back Pain
CE Mark approval for the HYDRAFIL System was granted based on a clinical study of 75 patients that showed that those treated with HYDRAFIL…
Read MoreQuoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study
ASHBURN, Va., May 22, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused…
Read MoreGeneDx Publishes Pioneering Vision for Applying AI to Genomics to Improve and Expedite Diagnosis of Genetic Disease at Scale
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the publication of a new article in…
Read MoreHHS layoffs create ‘clear opportunity’ for local health, life sciences companies to add talent — BHI CEO Rich Bendis shares insights with the Washington Business Journal
By Sara Gilgore – Staff Reporter, Washington Business Journal - May 21, 2025 - Once the Department of Health and Human Services unveiled a…
Read MoreJune 10, 2025 Webinar: Turning Uncertainty to Opportunity: Mastering Government Funding in 2025
Navigating the Shifting Federal Funding Landscape Strategies, Insights, and AI-Driven Approaches for Winning Non-Dilutive Capital The federal funding landscape is undergoing a significant transformation.…
Read MoreAshburn’s Quoin Pharma’s QRX003 Granted Orphan Drug Status in Europe for Netherton Syndrome
ASHBURN, Va., May 20, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage, specialty pharmaceutical company…
Read MoreREGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million
ROCKVILLE, Md., May 19, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the closure of a non-dilutive, limited recourse royalty bond agreement of up to $250 million with Healthcare…
Read MoreAltimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD)
GAITHERSBURG, Md., May 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced…
Read MoreSenseonics Announces Commencement of $50 Million Public Offering of Common Stock and Concurrent Private Placement
GERMANTOWN, Md., May 15, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing…
Read MoreVPM: Mark Esser wants to make Charlottesville the Silicon Valley of biotech
By Phil Liles: The University of Virginia has named Mark Esser as the first chief scientific officer of the upcoming Paul and Diane Manning Institute…
Read MoreFDA Accepts REGENXBIO’s Application for Priority Review of Gene Therapy for Hunter Syndrome (MPS II)
ROCKVILLE, Md., May 13, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA)…
Read MoreAltimmune Secures Up to $100 Million in Credit Facility from Hercules Capital
GAITHERSBURG, Md., May 13, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases,…
Read More